

New business area: Aegirbio's technology can demonstrate immunity to Corona virus

Aegirbio's technology opens up new possibilities in the control of immunity after infection or vaccination against viruses. The Veritope molecules that are a part of Aegirbio's activity in the precise dosing of biological drugs can be used as a basis in tests of patients' immunity (antibodies). One example is immunity to Coronavirus.

With its Veritope molecules, Aegirbio can mimic the proteins that biological drugs bind to and thus detect, in a simple blood test, concentrations of these drugs. Similarly, Veritopes can very accurately mimic the proteins that the body's own immune system binds to in immunity to, for example, Coronavirus after an infection or vaccination.

Aegirbio now has the opportunity to open up a whole new business area in antibody testing against bacteria and viruses by offering accurate tests based on Veritoper's ability to copy the parts of viruses and bacteria that the immune system's antibodies bind to and thus demonstrate genuine immunity to the disease. In the long term, this will be an important part of the basic tests that will be needed globally.

"We have since discussed the outbreak of the Coronavirus, the power of Aegirbio in being able to offer tests of people's immunity where Veritope, with its ability to precisely mimic the naturally occurring binding sites on viruses and bacteria, has the opportunity to give more accurate results than today's test methods. The combination of our key technologies Veritope™ and MagniaReader MIA allows us to open very secure immunity testing even outside the Central Laboratory. The speed with which we have succeeded in investigating and deciding how to proceed is enormous. It is also gratifying that we will be able to contribute to global health in a decisive way," says Anders Ingvarsson, acting CEO of Aegirbio

"A fundamental challenge facing us during this pandemic is to determine who has already had the virus, even if they were asymptomatic. Public health decisions will need this information, and it can be gleaned from the antibodies in the blood after viral infection. Detecting those antibodies with Veritopes is essentially the same scientific problem we deal with when therapeutic dose monitoring antibody drugs. The technology platforms that we have assembled in Aegirbio are perfect for this challenge and may well provide greater accuracy than the first wave of tests being rushed to market. Getting it right is of utmost importance. To this end, Abreos Biosciences has submitted proposals to the US government to accelerate the early Veritope discovery work and its integration to the MagniaReader platform." says Dr Bradley Messmer, CEO and main owner of Abreos Biosciences.

For additional information please contact the CEO of LifeAssays AB, Anders Ingvarsson 46 46 286 54 00
or email: info@lifeassays.com

About LifeAssays®. NGM-listed LifeAssays® ABs business idea is to develop, manufacture and sell diagnostic systems based on the Company proprietary and patented technology platform, MagnetImmunoAssay (MIA). The Company delivers safe and robust systems for quick and reliable analysis in human- and veterinary medicine. For more details please go to www.lifeassays.com